El interés en corto de Satellogic da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Satellogic. Los datos de interés en corto se actualizan cada dos semanas.

Satellogic (NASDAQ:SATL) Bolsa, Informe de interés en corto

Satellogic

Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.

Satellogic Inc. - Class A Ordinary Shares

Satellogic Inc

Zozo Inc

WIIM

Bioventus shares are trading higher after JP Morgan upgraded the stock from Underweight to Neutral and raised its price target from $12 to $13.

PWOD

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

XXII

EXEL

Exelixis shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral.

Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) reported quarterly losses of $(11.35) per share.

Earnings

News

SONN

Sonnet BioTherapeutics FY 2024 GAAP EPS $(11.35)

Lake Street analyst Ryan Meyers maintains Mama`s Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) with a Buy and raises the price target from $10 to $11.

Price Target

Analyst Ratings

MAMA

Lake Street Maintains Buy on Mama's Creations, Raises Price Target to $11

The Health Resources and Services Administration (HRSA) has warned Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) about its proposed credit model for certain outpatient drugs under the 340B program.
HRSA asserts that the credit system, beginning on January 6, 2025, violates Sanofi's legal obligations under the 340B statute.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system" rel="noreferrer noopener">Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System</a>
Sanofi <a target="_blank" href="https://www.hrsa.gov/sites/default/files/hrsa/opa/dec-13-2024-hrsa-letter-sanofi.pdf" rel="noreferrer noopener">announced</a> in a November 22, 2024, notice that it would introduce a credit model for covered outpatient drugs for specific covered entities, including disproportionate share hospitals, critical access hospitals, rural referral centers, and sole community hospitals.
Under this plan, these entities would pay the Wholesale Acquisition Cost (WAC) upfront and later submit purchase and claim data to receive a credit representing the 340B price difference. Starting March 1, 2025, this model would include consolidated health centers.
Additionally, Sanofi's notice requires hospitals to submit healthcare encounter data to verify claims based on HRSA's 1996 patient guidelines, effective March 1, 2025.
The criteria include ensuring the individual receiving the drug is under the covered entity's care and that prescriptions are tied to services provided by the entity.
HRSA emphasized that the 340B statute establishes a ceiling price as the maximum amount covered entities can be charged for outpatient drugs. Any manufacturer must offer drugs at or below this ceiling price without imposing additional conditions. Sanofi's proposed credit model, which mandates payment above this price without prior approval, directly contradicts the statute.
The agency also warned that proceeding with the credit proposal could lead to severe consequences for Sanofi. These include potential termination of its Pharmaceutical Pricing Agreement (PPA) and civil monetary penalties.
The 340B statute allows sanctions for manufacturers that knowingly overcharge covered entities.
HRSA has instructed Sanofi to halt the implementation of this credit model immediately and provide confirmation by December 20, 2024.
Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) filed a lawsuit against HRSA and the U.S. Department of Health and Human Services, alleging that HRSA's rejection of its proposed rebate model for the 340B Drug Pricing Program <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42248288/bristol-myers-squibb-files-lawsuit-against-us-agency-for-overreach-in-340b-drug-pricing-program" rel="noreferrer noopener">violates federal law</a>.
Price Action: At last check Tuesday, SNY stock was up 4.14% at $47.79 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42514598/hubspots-ai-powered-tools-set-to-drive-smb-growth-and-crm-innovation-analyst-says" target="_blank" rel="noreferrer noopener">HubSpot To Dominate SMB CRM Space With AI-Driven Platform, Says BofA Analyst</a></li>
</ul>
Image by HJBC via Shutterstock

Government

Large Cap

Health Care

General

Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Overweight rating and announces Price Target of $17.

Initiation

AQST

Cantor Fitzgerald Initiates Coverage On Aquestive Therapeutics with Overweight Rating, Announces Price Target of $17

RVPH

Reviva Pharmaceuticals shares are trading lower after the company announced a $18 million public offering.

Pfizer Expects No Material US Policy Changes Regarding Vaccines From  Incoming Administration In 2025

Traders seeking short-term opportunities in a changing economy are turning to leveraged and inverse ETFs as tools to capitalize on market shifts, particularly following the recent election. At the most recent virtual <a href="https://www.benzinga.com/events/">Benzinga</a> boot camp hosted by Direxion, analysts spotlighted strategies and trends driving interest in these financial instruments while emphasizing their role in tactical trading.
During the session, Gianni Di Poce, an analyst at The Mercator LLC, and Eliott Wellenbach, a senior vice president and institutional ETF strategist at Direxion, discussed the performance of leveraged ETFs in semiconductors, Chinese markets, and single-stock opportunities.
See Also: <a href="https://www.benzinga.com/24/12/42528079/this-high-yield-dividend-etf-is-undergoing-a-harsh-reversal-signaling-bearish-trends-here-what-you-need-to-know">This High Yield Dividend ETF Is Signaling Bearish Trends: Is Trouble Brewing?</a>
<h3 class="wp-block-heading">Why Traders Are Watching Semiconductors</h3>
The semiconductor industry remains a focal point for traders as artificial intelligence and quantum computing developments continue to shape the market. Di Poce pointed to the Philadelphia Semiconductor Index as a case study, noting its upward trend.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Trading the New Trump Era: Leveraged ETF Bets for a Changing Economy" width="500" height="281" src="https://www.youtube.com/embed/r42G6s6ysEw?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
"When looking at trends, higher highs and higher lows indicate where the bigger directional moves are likely to occur," Di Poce said. He emphasized the value of Direxion's triple-leveraged SOXL ETF for bullish opportunities while also recognizing potential on the bearish side with SOXS, depending on short-term market movements.
Wellenbach added context from fund flows, explaining that SOXL has been among the top ETFs for inflows this year, reflecting investor confidence in semiconductor performance. "SOXL is our second-largest fund by assets under management," he said, acknowledging recent weekly outflows as traders locked in profits.
<h3 class="wp-block-heading">China's Rebound Draws Interest</h3>
China's markets have also garnered attention after periods of volatility and downtrends. Di Poce highlighted the FTSE China 50 Index, explaining how stimulus measures and broader monetary shifts have contributed to a potential trend reversal.
"You had lower lows and lower highs for months, but that began to change earlier this year," Di Poce noted, pointing to recent higher lows as a signal of recovery. Direxion's YINN, a bullish China ETF, has seen notable inflows, aligning with the market's upward trajectory.
Wellenbach echoed this sentiment, adding that YINN became one of Direxion's top-performing funds following the Federal Reserve's rate adjustments. "The September easing helped shift global monetary flows, and traders recognized that opportunity," he said.
<h3 class="wp-block-heading">Single-Stock ETFs: A Growing Tool</h3>
Another focus of the session was single-stock ETFs. Di Poce discussed opportunities in high-profile names like Apple, Alphabet, and Tesla, noting their recent technical patterns.
"Apple broke through resistance and hit new highs, while Tesla confirmed its bull trend after months of declines," Di Poce said. Leveraged funds like AAPU for Apple and TSLU for Tesla offer traders tools to take short-term positions on individual stocks.
Wellenbach highlighted the increasing popularity of these ETFs, saying, "We've seen assets in single-stock funds grow from $1 billion to $6 billion this year as traders look for ways to express short-term convictions or hedge concentrated positions."
<h3 class="wp-block-heading">Education And Strategy Remain Crucial</h3>
Both analysts emphasized the importance of understanding how leveraged ETFs function throughout the event. Wellenbach stressed their role as short-term tools and warned traders against a buy-and-hold approach due to the funds' daily rebalancing.
"These are powerful instruments, but you need to know what you own and how they work," Wellenbach said. Di Poce echoed this caution, reminding traders to manage risk. "Leverage can amplify gains, but it can also amplify losses. You can't afford to stay wrong for long."
Now Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42529095/bitcoin-crash-could-trigger-stock-market-decline-in-2025-warns-expert-im-very-worried-that-people-overextended-themselves">Bitcoin Crash Could Trigger Stock Market Decline In 2025, Warns Expert</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

ETFs

AAPU

SOXL

Direxion Daily Semiconductor Bear 3X Shares

SOXS

YINN

EXCLUSIVE: Leveraged ETFs Offer Short-Term Edge As Traders Eye Semiconductors, China, And Quantum Tech In Post-Election Market

UBS analyst Seth Gilbert initiates coverage on Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) with a Neutral rating and announces Price Target of $32.

OTEX

UBS Initiates Coverage On Open Text with Neutral Rating, Announces Price Target of $32

WIMI

WiMi Hologram shares are trading higher after the company announced it's developing a new design solution for simulating quantum computing concepts using FPGA

U.S. retail sales exceeded expectations in November, highlighting consumers&#8217; continued resilience in spending as <a href="https://www.benzinga.com/news/econ-s">the holiday season began.</a>
Retail and food services sales rose to $724.6 billion in November, a 0.7% increase from October, according to seasonally adjusted advance estimates released Tuesday.
The monthly growth outpaced market expectations of a 0.5% rise, based on consensus estimates from TradingEconomics.
<h3 class="wp-block-heading">Auto Sales Rocket</h3>
On a year-over-year basis, retail sales grew by a remarkable 3.8%, the highest since December 2023, up from the upwardly revised 2.9% in October.
Excluding motor vehicles and parts, retail sales advanced by 0.2% month-over-month, holding steady from October but missing expectations of 0.4%. When stripping out gasoline, motor vehicles, and parts, sales also rose by 0.2% in November, steady from October and below the expected 0.4%. 
Within spending categories, motor vehicle and parts recorded the largest monthly gain, with sales increasing 2.6% month-over-month and 6.5% year-over-year. 
Other increases were found in nonstore retailers, up 1.8% month-over-month and sporting goods, hobby, musical instrument, and book stores, up 0.9% on the month. 
On the other hand, miscellaneous store retailers registered the steepest monthly decline, with sales contracting 3.5%, followed by food services and drinking places, which saw sales fall 0.4%.
<h3 class="wp-block-heading">Market Reactions</h3>
The U.S. dollar index (DXY) which is tracked by the&nbsp;Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) strengthened by 0.2%, following the data. 
Treasury yields ticked higher, with the 10-year benchmark up by 2 basis points to 4.42%. 
Futures on major U.S. equity indices edged lower in Tuesday&#8217;s premarket trading, with S&amp;P 500 contracts down 0.4% and the tech-heavy Nasdaq 100 slipping 0.5%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42514008/fed-poised-to-cut-interest-rates-by-0-25-this-week-heres-why-your-focus-should-shift-to-other-signals">Fed Poised To Cut Interest Rates By 0.25% This Week: Here&#8217;s Why Your Focus Should Shift To Other Signals</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Retail Sales

Econ #s

Economics

PowerShares DB US Dollar Index Bullish Fund

November Retail Sales Hit 11-Month Highs, Signal Strong Holiday Demand

GILD

Gilead Announces FDA Breakthrough Therapy Designation For Trodelvy For Second-Line Treatment Of Extensive-Stage Small Cell Lung Cancer

BMEA

Biomea Fusion shares are trading lower. The company reported Phase II results for Icovamenib in Type 2 diabetes.

Lakeside's Hupan Pharmaceutical Signs $1.5M Sales Agreement With Sinopharm Holding Hubei New Special Medicine

CoinShares CEO Jean-Marie Mognetti expressed confidence regarding the future of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ETFs and other cryptocurrencies such as Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) under the incoming administration of President-elect Donald Trump.
What Happened: Mognetti highlighted the substantial inflows into U.S. Bitcoin ETFs following the election. He noted that the Bitcoin ETF sector has witnessed 12 consecutive weeks of net inflows, a trend unseen since 2021. Mognetti anticipates that the new administration will maintain a positive stance towards cryptocurrency, potentially benefiting Ethereum and other digital coins, CNBC <a href="https://www.cnbc.com/video/2024/12/17/coinshares-ceo-on-the-expectations-crypto-will-continue-to-thrive-under-president-elect-trump.html">reported</a> on Tuesday. 
&#8220;The Trump administration coming up in January or February is nourishing a lot of hope,&#8221; Mognetti said.
See Also: <a href="https://www.benzinga.com/24/12/42495782/crypto-market-predicted-to-surge-to-all-time-highs-by-late-2025-but-a-30-drop-in-bitcoin-prices-could-come-first?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Crypto Market Predicted To Surge To All-Time Highs By Late 2025, But A 30% Drop In Bitcoin Prices Could Come First</a>
Mognetti also pointed out that the U.S. market has been lacking in crypto products since 2014, when the first application was submitted. The SEC has been cautious in approving new products, but Mognetti believes this is changing, allowing more issuers to properly introduce coins. As the market evolves, he expects increased investment demand for cryptocurrencies, driven by greater market education and regulatory support. 
Why It Matters: The optimism from Mognetti aligns with recent statements from Michael Saylor, co-founder of MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), who emphasized the<a href="https://www.benzinga.com/24/12/42522606/trump-is-serious-about-creating-a-bitcoin-reserve-says-microstrategys-michael-saylorurges-to-buy-btc-before-it-goes-up-by-100x"> incoming Trump administration&#8217;s seriousness</a> about establishing a U.S. strategic Bitcoin reserve. Saylor urged investors to &#8220;buy it now and own the future,&#8221; suggesting that capital will flow into digital assets and the Bitcoin network.
Furthermore, President-elect Trump has pledged to <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42480856/donald-trump-pledges-to-do-something-great-with-crypto-heres-what-hes-done-so-far">&#8220;do something great with crypto,&#8221;</a> indicating a significant shift in U.S. policy on digital assets. Trump emphasized the need for the U.S. to stay ahead of global competitors, particularly China, in embracing cryptocurrency. This potential policy shift could lead to increased regulatory support and market education, fostering a more favorable environment for cryptocurrencies like Bitcoin and Ethereum. 
Price Action: According to <a href="https://pro.benzinga.com">Benzinga Pro</a> data, at 8:42 am ET, Bitcoin was up at $1,07,469.30 while Ethereum was trading at $4,008.83. Meanwhile, Bitcoin based ETFs were also seeing an upward movement. Bitwise Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITB#NYSE">BITB</a>) was up by 1.56%, iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) was up by 1.66% and Grayscale Bitcoin Trust (Btc) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#NYSE">GBTC</a>) was trading 1.40% higher.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42496852/benzinga-bulls-and-bears-tesla-nvidia-microstrategy-dollar-tree-and-dogecoin-prediction-of-18-in-wild-scenario?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla, Nvidia, MicroStrategy, Dollar Tree, And Dogecoin Prediction Of $18 In &#8216;Wild&#8217; Scenario: Benzinga Bulls</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Markets

$BTC

$ETH

$SOL

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

GBTC

IBIT

MSTR

CoinShares CEO Optimistic About Bitcoin ETFs, Ethereum Under Trump

LODE

Comstock shares are trading higher after the company announced it secured a $3 million incentive from Oklahoma to build headquarters and an advanced renewable fuel facility.

Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) shares are trading lower premarket today. On Monday, the company provided fourth-quarter guidance, expecting EPS of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42519618/nucor-announces-guidance-for-the-fourth-quarter-of-2024-earnings" rel="noreferrer noopener">$0.55 &#8211; $0.65 vs. the consensus of $0.86</a>.
The primary factor driving the expected earnings decline is lower earnings in the steel mills segment due to decreased<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> volumes and lower average selling prices</a>.
The company projects earnings in the steel products segment to decline, reflecting the same trends. However, the raw materials segment is anticipated to see an increase in earnings, excluding the impairment charge from the third quarter of 2024.
Nucor reported net earnings of&nbsp;$1.05&nbsp;per share in the&nbsp;third quarter&nbsp;of 2024 and&nbsp;$3.16&nbsp;per share in the&nbsp;fourth quarter&nbsp;of 2023.
Notably, during the <a target="_blank" href="https://www.benzinga.com//node/41439525" rel="noreferrer noopener">third-quarter earnings release</a>, Nucor stated that it expects the fourth quarter&nbsp;earnings per share to decrease compared to $1.05&nbsp;reported for the&nbsp;third quarter amid decreased steel mill segment earnings caused by lower average selling prices and decreased volumes.
In the fourth quarter, Nucor repurchased around 2.1 million shares at an average price of $149.81 per share, bringing the total year-to-date repurchases to 13.1 million shares at an average price of $168.75 per share.
Nucor has returned over $2.73 billion to stockholders through share repurchases and dividend payments so far this year.
In October, the company reported quarterly adjusted earnings of $1.49 per share, which beat the analyst consensus estimate of $1.47 and revenue of $7.44 billion, which beat the analyst consensus estimate of $7.28 billion.
Nucor plans to release its fourth-quarter results on&nbsp;Monday, January 27, 2025.
Investors can gain exposure to the stock via&nbsp;VanEck Steel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLX#NYSE">SLX</a>)&nbsp;and First Trust Materials AlphaDEX Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXZ#NYSE">FXZ</a>).
Price Action: NUE shares are down 1.51% at $122.29 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42527692" target="_blank" rel="noreferrer noopener">Mission Accomplished: Lockheed Martin&#8217;s GPS III SV07 Successfully Deployed</a></li>
</ul>

Equities

Guidance

Movers

Nucor's Q4 Guidance Misses The Mark, Hit By Steel Slowdown; Stock Slides

Satellogic (SATL) has released an update. Satellogic Inc. announces the resignation of board member Howard Lutnick, following his nomination to ser...

Satellogic Inc. Board Changes Amidst Leadership Transition

Satellogic (SATL) has released an update. Satellogic, a leader in high-resolution Earth Observation, reported a 114% revenue growth in the first ha...

Satellogic Reports Strong Growth and Strategic Advances

Satellogic: Little News, Stock Surge Makes Little To No Sense

Satellogic announces $10M private placement made by single institutional investor

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Omnicom (OMC) agreed to acquire Interp...

Omnicom to acquire Interpublic, China to investigate Nvidia: Morning Buzz

An announcement from Satellogic ( ($SATL) ) is now available. Satellogic Inc. has entered into a share purchase agreement with an unnamed purchaser...

Satellogic Inc. Enters Share Purchase Agreement to Bolster Market Position

Satellogic files to sell 3.57M Class A ordinary shares for holders

17:08 EST Satellogic (SATL) files to sell $150M of Class A ordinary shares Published first on TheFly – the ultimate source for real-time, market-mo...

Satellogic files to sell $150M of Class A ordinary shares

Satellogic ( ($SATL) ) has issued an announcement. Maxar Intelligence and Satellogic have entered into a strategic partnership to enhance national ...

Maxar and Satellogic Forge Partnership to Boost National Security Surveillance

Cantor Fitgerald to pay $6.75M to settle SEC probe on SPAC dislosures

AAPL

AMZN

ANGO

BNED

HOOD

MDLZ

MOMO

MSFT

NVDA

NXPL

PLTR

POST

PRCH

PYPL

RDDT

REAL

RIOT

RVNC

SATL

VIEWQ

VWAGY

VWAPY

Press Releases

Satellogic Reports Full Year 2023 Financial Results and Provides Business Update

Satellogic Signs Letter of Intent with O.N.E. Amazon to Support Building the Internet of Forests

Satellogic Releases Open Dataset for AI Model Training

Satellogic Expands Reach: New Sales Channel through Global Data Marketplace

Satellogic Welcomes Kelly Kennedy to Board of Directors

Satellogic Selected for NASA's Commercial SmallSat Data Acquisition Program

SynMax Expands Contract With Satellogic to Drive Company's Oil and Natural Gas Production Monitoring Offering

Satellogic Announces $10 Million Private Placement Made By a Single Institutional Investor

Satellogic Announces Closing of $10 Million Private Placement and Filing of Shelf Registration Statement

Maxar Intelligence and Satellogic Announce Tasking Partnership to Support National Security Missions

Comments

Satellogic

Interés en corto

Satellogic (NASDAQ:SATL) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL